Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SetPoint Medical Gains FDA Nod to Continue RESET-RA Study - Orthopedic Design & Technology
OEM News

SetPoint Medical Gains FDA Nod to Continue RESET-RA Study

Evaluates vagus nerve stimulation to treat rheumatoid arthritis (RA).

SetPoint Medical has gained U.S. Food and Drug Administration (FDA) approval to continue its RESET-RA clinical study.
 
The study gained Investigational Device Exemption (IDE) approval from the FDA to evaluate SetPoint’s therapeutic platform for rheumatoid arthritis (RA). It began in January 2021.
 
The RESET-RA study will evaluate safety and efficacy of SetPoint’s platform for moderate-to-severe RA in patients who are incomplete responders or intolerant to biologic or targeted synthetic disease modifying anti-rheumatic drugs (DMARDs).
 
The study will enroll up to 250 patients at 40 U.S. sites in two stages with an interim analysis after Stage 1’s completion. Enrollment of 60 patients in Stage 1 finished in March 2022 at 18 U.S. sites.
 
The FDA approved study continuation without changes to the study protocol after review of Stage 1 safety and efficacy outcomes.
 
“This is another significant milestone for SetPoint Medical as we continue to develop this novel treatment option for RA patients,” David Chernoff, MD, chief medical officer of SetPoint told the press. “There is a significant unmet medical need for new treatment alternatives for RA patients whose disease activity is inadequately controlled with conventional biologic or synthetic DMARDs. We look forward to enrolling the remaining 190 patients in the second stage of the study.”
 
According to the company, RESET-RA is the first study of its kind to assess vagus nerve stimulation to treat RA. The vagus nerve plays a critical role in maintaining inflammatory balance. The RESET-RA study is actively recruiting following approval for Stage 2.

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters